Type Iia Topoisomerase Inhibition by a New Class of Antibacterial Agents.
Bax, B.D., Chan, P.F., Eggleston, D.S., Fosberry, A., Gentry, D.R., Gorrec, F., Giordano, I., Hann, M.M., Hennessy, A., Hibbs, M., Huang, J., Jones, E., Jones, J., Brown, K.K., Lewis, C.J., May, E.W., Saunders, M.R., Singh, O., Spitzfaden, C., Shen, C., Shillings, A., Theobald, A.F., Wohlkonig, A., Pearson, N.D., Gwynn, M.N.(2010) Nature 466: 935
- PubMed: 20686482 
- DOI: https://doi.org/10.1038/nature09197
- Primary Citation of Related Structures:  
2XCO, 2XCQ, 2XCR, 2XCS, 2XCT - PubMed Abstract: 
Despite the success of genomics in identifying new essential bacterial genes, there is a lack of sustainable leads in antibacterial drug discovery to address increasing multidrug resistance. Type IIA topoisomerases cleave and religate DNA to regulate DNA topology and are a major class of antibacterial and anticancer drug targets, yet there is no well developed structural basis for understanding drug action ...